B.Riley Financial Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $51

Futu NewsJan 3 15:33 · Ratings

Arrowhead Pharmaceuticals: Strong Growth Potential Backed by SiRNA Therapeutics and Financial Stability

TipRanksJan 3 13:45

2024's 'Biggest Loses' That Could See Reversal in 2025

Seeking AlphaDec 23, 2024 23:00

Express News | Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of Aro-Inhbe for the Treatment of Obesity

BreakingsDec 23, 2024 20:30

Arrowhead Pharmaceuticals Insider Sold Shares Worth $567,486, According to a Recent SEC Filing

MT NewswiresDec 23, 2024 17:03

H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $80

Futu NewsDec 21, 2024 03:31 · Ratings